Literature DB >> 21091638

The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators.

Petra Koefinger, Christian Wels, Shripad Joshi, Sabine Damm, Elisabeth Steinbauer, Christine Beham-Schmid, Sasa Frank, Helmut Bergler, Helmut Schaider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21091638      PMCID： PMC3190298          DOI： 10.1111/j.1755-148X.2010.00807.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  10 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 2.  Epithelial cell plasticity in development and tumor progression.

Authors:  J P Thiery; D Chopin
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

3.  Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.

Authors:  G Li; H Schaider; K Satyamoorthy; Y Hanakawa; K Hashimoto; M Herlyn
Journal:  Oncogene       Date:  2001-12-06       Impact factor: 9.867

4.  Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail.

Authors:  Stefan Grotegut; Dietrich von Schweinitz; Gerhard Christofori; François Lehembre
Journal:  EMBO J       Date:  2006-07-13       Impact factor: 11.598

Review 5.  Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes.

Authors:  Jonas Fuxe; Theresa Vincent; Antonio Garcia de Herreros
Journal:  Cell Cycle       Date:  2010-06-15       Impact factor: 4.534

6.  Shifts in cadherin profiles between human normal melanocytes and melanomas.

Authors:  M Y Hsu; M J Wheelock; K R Johnson; M Herlyn
Journal:  J Investig Dermatol Symp Proc       Date:  1996-04

7.  Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.

Authors:  Keith Hoek; David L Rimm; Kenneth R Williams; Hongyu Zhao; Stephan Ariyan; Aiping Lin; Harriet M Kluger; Aaron J Berger; Elaine Cheng; E Sergio Trombetta; Terence Wu; Michio Niinobe; Kazuaki Yoshikawa; Gregory E Hannigan; Ruth Halaban
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

8.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

9.  Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression.

Authors:  M Hsu; T Andl; G Li; J L Meinkoth; M Herlyn
Journal:  J Cell Sci       Date:  2000-05       Impact factor: 5.285

10.  E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro.

Authors:  A Tang; M S Eller; M Hara; M Yaar; S Hirohashi; B A Gilchrest
Journal:  J Cell Sci       Date:  1994-04       Impact factor: 5.285
  10 in total
  15 in total

Review 1.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 2.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

3.  Slug expression during melanoma progression.

Authors:  Stephanie H Shirley; Victoria R Greene; Lyn M Duncan; Carlos A Torres Cabala; Elizabeth A Grimm; Donna F Kusewitt
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

4.  TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.

Authors:  Michele B Weiss; Ethan V Abel; Melanie M Mayberry; Kevin J Basile; Adam C Berger; Andrew E Aplin
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

Review 5.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

6.  Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes.

Authors:  Joanne Soong; Glynis Scott
Journal:  J Cell Sci       Date:  2012-11-30       Impact factor: 5.285

7.  Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.

Authors:  N M Ayoub; M R Akl; P W Sylvester
Journal:  Cell Prolif       Date:  2013-08-23       Impact factor: 6.831

Review 8.  Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.

Authors:  Linli Zhou; Kun Yang; Thomas Andl; R Randall Wickett; Yuhang Zhang
Journal:  J Cancer       Date:  2015-06-23       Impact factor: 4.207

Review 9.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

10.  The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Authors:  Nina Fenouille; Mélanie Tichet; Maeva Dufies; Anaïs Pottier; Ariane Mogha; Julia K Soo; Stéphane Rocchi; Aude Mallavialle; Marie-Dominique Galibert; Amir Khammari; Jean-Philippe Lacour; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.